Galmed Pharma receives non-compliance letter from Nasdaq

Jun. 17, 2022 4:21 PM ETGalmed Pharmaceuticals Ltd. (GLMD)By: Dania Nadeem, SA News Editor
  • Galmed Pharma (NASDAQ:GLMD) said on Friday it had received a letter from the Nasdaq saying that the Company was not in compliance with the minimum bid price requirement for continued listing, which requires listed securities to maintain a minimum bid price of $1.00 per share.
  • The Company has until December 12 to regain compliance with the minimum bid price requirement.
  • The Company can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum of ten consecutive business days, it added.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.